After showcasing our fierce 15 last year, Billboard runs the table back and presents this year’s Hip-Hop/R&B Artists to watch Class of 2021.
Last year, Billboard watched a bevy of rookies take a leap forward and graduate into stardom. Rod Wave, Jack Harlow, and Don Toliver’s chart dominance helped solidify their standing in the hip-hop game while R&B singer Kaash Paige exuded promise on her sizzling debut. Along with standout campaigns in 2020, the hip-hop community mourned the losses of Brooklyn’s Pop Smoke and Chicago’s King Von, as both stars were victims of gun violence. With 2021 currently in session, a new breed of neophytes looks to cause a stir. After showcasing our fierce 15 last year, Billboard runs the table back and presents this year’s Hip-Hop/R&B Artists to watch Class of 2021. Check out our list below.
In 2020, Blxst rocketed to success when fans unwrapped his eight-track project No Love Lost. The Cali polymath doesn’t shy away from messy topics, working through heartbreak and relationship woes with elastic ease. Fortunately, Blxst doesn’t allow his losses to define him, as he proves to be a slithery Casanova on “Wrong or Right,” “Overrated” and “Be Alone.” His skill for hitmaking shines on the project’s deluxe edition, as he recruits West Coast all-stars Dom Kennedy (“Got It All”) and Ty Dolla $ign and Tyga (“Chosen”) for his daily escapades. — CARL LAMARRE
What’s now clear: an injection with either vaccine, both of which use mRNA technology, can feel more intense than other routine vaccinations (such as the flu shot) — with side effects for some recipients such as pain, headache, and fatigue. And this may be especially true for Moderna’s vaccine: About 16 percent of people who got the shot in clinical trials experienced a “severe” adverse reaction, a classification the FDA uses to refer to side effects that require medical attention and prevent people from going about their daily activities. “We should anticipate that if you got vaccinated that day, you may not want to go to work,” Peter Hotez, the dean of the National School of Tropical Medicine at Baylor College, said of the vaccines. That’s why health systems are being warned to stagger immunizing their workforces, to avoid “potential clustering of worker absenteeism,” as the vaccine expert group advising the Centers for Disease Control and Prevention (CDC) put it. These side effects are known as reactogenicity, and vaccine developers and regulators allow for some level of reactogenicity in all approved vaccines. They can be a sign of the body’s immune response kicking into gear, said Saad Omer, director of the Yale Institute for Global Health.
After months of waiting, we finally have detailed information on the safety and efficacy of the first Covid-19 vaccines that will be distributed in America. On Thursday, a committee that advises the Food and Drug Administration will meet to determine whether the Moderna vaccine should get an emergency use authorization. Ahead of the decision, the agency shared the most comprehensive data to date on what we know about the shot. The same process happened last week with the Pfizer/BioNTech vaccine, which is now being rolled out across America following an EUA Friday night. While both vaccines had already been shown to be highly effective, the new data provides a much more granular picture of their side effects and safety profiles.
“Think about [reactogenicity] as mouth wash — it’s hurting while it’s working,” Omer said. “The key is to prepare people to know this will happen — this may hurt a little, give you a bit of fever — but these are short-term, known side effects that you need to be aware of.” The stakes for clearly communicating information about each vaccine’s risks and benefits are high: More than a quarter of Americans reported that they would probably or definitely refuse to take a Covid-19 vaccine, according to a late-summer survey by the Kaiser Family Foundation, even if it were freely available and deemed safe by regulators. And with the pandemic spreading further and faster in America than just about anywhere else in the world, it’s critical that people don’t feel caught off guard by the side effects or spread misinformation about the vaccine. To achieve that, transparency is key, said Brendan Nyhan, a Dartmouth professor of political science who has been thinking about how to build trust in the Covid-19 vaccines. “Millions of people are going to get this vaccine and we know huge numbers of people are going to have normal side effects, which are often indicating that the vaccine is working. We want to build trust with people so there are no surprises when that happens.” In that spirit, here’s what we know about the side effects of these two shots and how to think about them. What mild and moderate side effects really mean Before we get into the weeds, it’s helpful to understand how these companies classify side effects in the first place. In general, vaccine developers seeking approval in the US market use the FDA’s “toxicity assessment scale” to grade side effects and other adverse events from 1 to 4, from mild and moderate to severe and life-threatening. Grade 1 “mild” side effects are generally easily tolerated and don’t interfere with a person’s regular activities. Grade 2 “moderate” effects may interfere with regular activities, grade 3 “severe” effects are incapacitating and need medical attention, and grade 4 are “potentially life-threatening,” usually requiring an emergency room visit or hospitalization. Let’s use the example of headache following vaccination. Here’s how the FDA would classify it: Mild: “No interference with activity”
Moderate: “Repeated use of nonnarcotic pain reliever > 24 hours or some interference with activity” Severe: “Any use of narcotic pain reliever or prevents daily activity” Potentially life-threatening: “ER visit or hospitalization” So a mild side effect is one you’d notice but doesn’t require any special care or keep you from living your life; a moderate side effect can keep you home from work but doesn’t warrant medical intervention; severe adverse events require medical care and definitely interfere with your normal life; and potentially life-threatening is just what it sounds like and usually involves a visit to or stay in the hospital. In vaccine studies, these events are broken down into “local” reactions (meaning they’re specific to one part of the body, like pain or tenderness where the vaccine is injected) and “systemic,” whole-body reactions (like fever or fatigue).
For a vaccine to win FDA approval, any reactions people have during clinical trials have to be mostly mild and moderate. And that’s because the safety bar for vaccines is really high, even compared to medicines.
Vaccines “are given to healthy people who have in many cases absolutely nothing wrong with them. And we are talking about [giving them] to literally billions of people. Even rare side effects if they’re serious matter enormously,” said Charles Weijer, a professor of medicine and an ethicist at Western University in Alberta, Canada. “We’re more willing to accept adverse effects [with drugs], provided those are counterbalanced by benefits to the patient.” Mostly mild and moderate side effects: that’s the safety profiles of both the Moderna and Pfizer/BioNTech vaccines — and that’s why the FDA in the US, and drug regulators in other countries around the world, are rushing to bring them to market. But there are important differences between the two vaccines. What we know about Moderna and Pfizer/BioNTech side effects Now, let’s look at the best data we’ve got on the vaccines. It comes from the FDA’s analyses of phase 2 and 3 clinical trials ahead of their emergency use authorization meetings on December 10 for Pfizer/BioNTech and December 17 for Moderna. (The companies also released their own data but we focused on the agency’s independent reviews here.) The reviews show the vaccines are both safe and that they’re wildly successful at preventing Covid-19 infections (with about a 95 percent efficacy rate). That’s important at a time when more than 3,000 Americans are dying from Covid-19 each day on average. They also give a sense of what side effects we might expect when these are rolled out. The Pfizer/BioNTech vaccine caused mild or moderate reactions in most people, but severe reactions were rare. Moderna didn’t share the details of its vaccine trial’s mild and moderate side effects, but the FDA said mild and moderate is how they’d characterize the bulk of them. A key difference with the Moderna vaccine, however, is that we know severe reactions were more common in the trials. Let’s get into what this means, but with a couple of caveats first. Because we have no head-to-head study of the two vaccines and the companies haven’t reported side effect data in the same way, doing apples-to-apples comparisons is tricky, said Hilda Bastian, an expert in reading medical evidence who has been analyzing the coronavirus vaccine data. The vaccines also come in different doses: 30µg in the case of Pfizer/BioNTech and 100µg with Moderna. While they’re supposed to be delivered in two shots per person, the time intervals are different: the Pfizer/BioNTech shots are three weeks apart and Moderna’s are four weeks. Pfizer/BioNTech and Moderna also tested their products on different populations. “Some of the differences affect risks and so could be affecting outcomes,” said Bastian. For example, there were more people of Hispanic/Latino background and with chronic lung disease in the Pfizer/BioNTech trial than the Moderna trial, she added. And in the real world, when the vaccines roll out to millions, the side effects may again look different. With all that in mind, here’s what we know about each shot. For Pfizer/BioNTech the most common side effects overall, according to the FDA’s analysis of the data, were local reactions at the site of injection (including pain, redness, swelling), fatigue, headache, muscle pain, chills, joint pain, and fever. Again, these were mostly classified as mild or moderate. Severe reactions, meanwhile, were rare — occurring in 0 to 4.6 percent of participants, depending on the specific side effect. (There were no severe fevers reported, for example, but 4.6 percent of the age 18-55 study participants experienced severe fatigue after the second dose of the vaccine.) In general, side effects popped up more after the second dose than the first. They also happened less frequently in people 55 and younger, the FDA said. You can see the breakdown of adverse events data in younger adults (18-55) in the chart below following dose 1, and if you click through, following dose 2. (Note: Pfizer/BioNTech found no potentially life-threatening (grade 4) adverse reactions linked to the vaccine in the population they analyzed for safety.) READ MORE: https://apple.news/AZvmcYrtKQWObJ00qk6feuw